Targeted inhibition in tumors with ALK dependency
Eunice L Kwak, Jeffrey W Clark, Alice T ShawMassachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: The oncogenic function of gene translocations involving the anaplastic lymphoma kinase (ALK) was first reported in rare subtypes of non-Hodgkin's lymphoma almost two decades...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-01-01
|
| Series: | Lung Cancer: Targets and Therapy |
| Online Access: | http://www.dovepress.com/targeted-inhibition-in-tumors-with-alk-dependency-a11914 |
| _version_ | 1818751125523791872 |
|---|---|
| author | Kwak EL Clark JW Shaw AT |
| author_facet | Kwak EL Clark JW Shaw AT |
| author_sort | Kwak EL |
| collection | DOAJ |
| description | Eunice L Kwak, Jeffrey W Clark, Alice T ShawMassachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: The oncogenic function of gene translocations involving the anaplastic lymphoma kinase (ALK) was first reported in rare subtypes of non-Hodgkin's lymphoma almost two decades ago. More recently, aberrant ALK signaling was found to be an oncogenic driver in subsets of non-small cell lung cancer (NSCLC), particularly in patients with little or no tobacco smoking history. The advent of molecularly targeted therapies that inhibit ALK has allowed the pairing of ALK inhibitors such as crizotinib as treatment for ALK-positive NSCLC, yielding dramatic responses and long-term disease control. The clinicopathologic features of ALK-driven NSCLC, the clinical development of ALK inhibitors, and the genetic determinants of acquired resistance to ALK inhibition are among the topics covered in this review.Keywords: targeted inhibition, tumors, ALK dependency |
| first_indexed | 2024-12-18T04:30:36Z |
| format | Article |
| id | doaj.art-47647a89cdb9463a8e88b0b7ed442845 |
| institution | Directory Open Access Journal |
| issn | 1179-2728 |
| language | English |
| last_indexed | 2024-12-18T04:30:36Z |
| publishDate | 2013-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Lung Cancer: Targets and Therapy |
| spelling | doaj.art-47647a89cdb9463a8e88b0b7ed4428452022-12-21T21:20:59ZengDove Medical PressLung Cancer: Targets and Therapy1179-27282013-01-012013default18Targeted inhibition in tumors with ALK dependencyKwak ELClark JWShaw ATEunice L Kwak, Jeffrey W Clark, Alice T ShawMassachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: The oncogenic function of gene translocations involving the anaplastic lymphoma kinase (ALK) was first reported in rare subtypes of non-Hodgkin's lymphoma almost two decades ago. More recently, aberrant ALK signaling was found to be an oncogenic driver in subsets of non-small cell lung cancer (NSCLC), particularly in patients with little or no tobacco smoking history. The advent of molecularly targeted therapies that inhibit ALK has allowed the pairing of ALK inhibitors such as crizotinib as treatment for ALK-positive NSCLC, yielding dramatic responses and long-term disease control. The clinicopathologic features of ALK-driven NSCLC, the clinical development of ALK inhibitors, and the genetic determinants of acquired resistance to ALK inhibition are among the topics covered in this review.Keywords: targeted inhibition, tumors, ALK dependencyhttp://www.dovepress.com/targeted-inhibition-in-tumors-with-alk-dependency-a11914 |
| spellingShingle | Kwak EL Clark JW Shaw AT Targeted inhibition in tumors with ALK dependency Lung Cancer: Targets and Therapy |
| title | Targeted inhibition in tumors with ALK dependency |
| title_full | Targeted inhibition in tumors with ALK dependency |
| title_fullStr | Targeted inhibition in tumors with ALK dependency |
| title_full_unstemmed | Targeted inhibition in tumors with ALK dependency |
| title_short | Targeted inhibition in tumors with ALK dependency |
| title_sort | targeted inhibition in tumors with alk dependency |
| url | http://www.dovepress.com/targeted-inhibition-in-tumors-with-alk-dependency-a11914 |
| work_keys_str_mv | AT kwakel targetedinhibitionintumorswithalkdependency AT clarkjw targetedinhibitionintumorswithalkdependency AT shawat targetedinhibitionintumorswithalkdependency |